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Abstract
 
A major group of natural killer (NK) T cells express an invariant V
 
a
 
14
 
1
 
 T cell receptor (TCR)
specific for the lipoglycan 
 
a
 
-galactosylceramide (
 
a
 
-GalCer), which is presented by CD1d.
These cells may have an important immune regulatory function, but an understanding of their
biology has been hampered by the lack of suitable reagents for tracking them in vivo. Here we
show that tetramers of mouse CD1d loaded with 
 
a
 
-GalCer are a sensitive and highly specific
reagent for identifying V
 
a
 
14
 
1
 
 NK T cells. Using these tetramers, we find that 
 
a
 
-GalCer–spe-
cific T lymphocytes are more widely distributed than was previously appreciated, with popula-
tions of largely NK1.1
 
2
 
 but tetramer-binding T cells present in the lymph nodes and the intes-
tine. Injection of 
 
a
 
-GalCer leads to the production of both interferon 
 
g
 
 and interleukin 4 by
nearly all NK T cells in the liver and the majority of the spleen within 2 h. These cells mostly
disappear by 5 h, and they do not reappear after 1 wk. Curiously, tetramer-positive thymocytes
do not rapidly synthesize cytokines, nor do they undergo decreases in cell number after lipid
antigen stimulation, although they express equivalent TCR levels. In summary, the data pre-
sented here demonstrate that 
 
a
 
-GalCer–specific NK T cells undergo a unique and highly com-
partmentalized response to antigenic stimulation.
Key words: antigen presentation • lipid antigen • T lymphocyte • natural killer cell • tetramer
 
Introduction
 
NK T cells are a specialized T cell subset that share some
traits with NK cells, such as the expression of the NK1.1
molecule, as well as characteristics of activated or memory
T cells. NK T lymphocytes may be classified into those that
are positively selected by CD1d, a nonclassical class I mole-
cule (for review see reference 1), and those that are CD1d
independent. Many members of this first population, the
CD1d-dependent NK T cells, express a semiinvariant
TCR composed of a specific V
 
a
 
14 rearrangement paired
preferentially with a diverse set of V
 
b
 
8.2, V
 
b
 
7, or V
 
b
 
2 re-
arrangements.
CD1d-dependent NK T cells are believed to be in-
volved in the regulation of immune responses as a result of
their potent ability to secrete cytokines. Evidence support-
ing a regulatory role for this population has been derived
from the study of several animal models of autoimmune
diseases (2–6) as well as from studies of human patients
with type I diabetes (7) and systemic sclerosis (8). CD1d-
dependent NK T cells also might be involved in some cir-
cumstances in the prevention of tumor metastases (9) and
the response to some infectious agents (10–13).
 
Currently, the natural ligand(s) for CD1d-restricted NK
T cells is unknown, although phosphoinositol-containing
compounds have been suggested to be natural ligands for
some of these cells (13–15). However, NK T cell reactivity
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to CD1d is greatly augmented by the glycosphingolipid
 
a
 
-galactosylceramide (
 
a
 
-GalCer)
 
1
 
 (16), obtained from an ex-
 
tract of the marine sponge 
 
Agelas mauritanius
 
. This com-
pound was initially identified in a screen for agents that
would prevent metastases of tumors to the livers of mice
 
(17). 
 
a
 
-GalCer is a specific agent for activating V
 
a
 
14
 
1
 
CD1d-dependent NK T cells (16, 18). It can be used to
manipulate both NK T cell and conventional T cell re-
sponses in mice (19, 20) and potentially in humans (21–23).
Although analysis for the coexpression of NK1.1 and an
 
a
 
/
 
b
 
 TCR is widely used to identify CD1d-dependent NK T
cells, there are several reasons why this method is not en-
tirely satisfactory. First, only three common inbred mouse
strains (B6, NZB, and SJL) express an allelic form of NK1.1
seen by the available NK1.1 mAb PK136 (1). Second,
NK1.1
 
1
 
 T cells may downregulate the NK1.1 marker upon
activation (24), making it difficult to follow these cells once
they have encountered antigen. Lastly, the NK1.1 marker
also is found on CD1d-independent T cells (25–27).
The development of MHC multimer technology has
provided a breakthrough in the ability to follow T cell
populations defined by their antigen specificity (28, 29).
The successful application of MHC dimer and tetramer re-
agents is due to the fact that a multimerized MHC–peptide
complex has a significantly higher avidity for the TCR
compared with a monomer (30, 31). Tetramers have been
used widely to obtain a detailed analysis of the distribution
and frequency of conventional CD4
 
1
 
 and CD8
 
1
 
 antigen-
specific T cells during a variety of immune responses. Mul-
timers also have been instrumental in identifying the recep-
tors for nonclassical class I molecules such as HLA-E (32),
 
Qa-1
 
b
 
 (33, 34), and HLA-G (35). There have been no pre-
vious reports, however, of the formation of multimeric an-
tigen-presenting molecules loaded with a lipid antigen.
Here we describe the formation and use of multimeric
CD1d molecules. We demonstrate that 
 
a
 
-GalCer–loaded
mouse (m)CD1d tetramers are a highly specific reagent for
detection of the in vivo response of NK T cells to a model
lipid antigen.
 
Materials and Methods
 
Reagents.
 
a
 
-GalCer was synthesized by the Pharmaceutical
Research Laboratory of Kirin Brewery Co. as described previ-
ously (17). A stock solution of 
 
a
 
-GalCer was diluted to 220 
 
m
 
g/
ml in 0.5% polysorbate-20 and 0.9% NaCl (hereafter referred to
as “vehicle”).
 
Dimeric CD1d–
 
a
 
-GalCer Complexes.
 
Soluble recombinant
 
mCD1d1 and human (h)CD1d proteins expressed in 
 
Drosophila
 
SC2 cells have been previously described (36, 37). For CD1d–
 
a
 
-
GalCer complex formation, mCD1d or hCD1d proteins were
incubated at room temperature for 12–18 h with threefold molar
excess of 
 
a
 
-GalCer. Dimeric CD1d complexes were formed
with 2B9 hamster mAb, which recognizes an epitope near the
COOH terminus of the recombinant mCD1d and hCD1d pro-
teins (Wang, C.-R., and O.V. Naidenko, unpublished data).
Dimeric complexes were purified by gel filtration on Superdex
200 column (Amersham Pharmacia Biotech). For flow cytome-
try analysis, the 2B9 antibody was biotinylated before dimer for-
mation, and streptavidin–tricolor or streptavidin–PE were used
for detection.
 
Tetrameric mCD1d–
 
a
 
-GalCer Complexes.
 
Tetrameric mCD1d
complexes were made in a baculovirus expression system as de-
scribed previously (38). A modified dual promoter baculovirus
transfer vector, pBacp10pH (39), was provided by Dr. J. Kappler
(Howard Hughes Medical Institute, University of Colorado, Den-
ver, CO). Recombinant mCD1d protein was produced with a
BirA tag followed by a 6-histidine tag. The amino acid sequence at
the COOH terminus is GSLHHILDAQKMVWNHRHHH-
HHH. To generate this construct, the mCD1d1 heavy chain was
 
cloned by PCR using 5
 
9
 
 primer CACGTCGACACATGCGG-
 
TACCTACCATGGCTG (Sal I site underlined) and two 3
 
9
 
 primers,
 
ACATGCATGCTTAACGATTCCACACCATTTTCTGTG-
 
CATCCAGAATATGATGCAGGGATCCCCAGTAGAGGAT-
 
GATATCCTG and CATGCATGCTTAGTGATGATGAT-
 
GATGATGACGATGATTCCACACCATTTTC (SphI sites
underlined). Mouse 
 
b
 
2 microglobulin (m
 
b
 
2m) was cloned using
the 5
 
9
 
 primer TCCGCTCGAGCAGCATGGCTCGCTCGGT-
GACC (XhoI site underlined) and the 3
 
9
 
 primer TGGTCCG-
GAGATCACATGTCTCGATCCCAGTAG (BspEI site under-
lined). In the expression construct, the mCD1d heavy chain was
expressed under the control of polyhedrin promoter, and m
 
b
 
2m
was expressed under the control of p10 promoter of baculovirus
transfer vector (39). The mCD1d/m
 
b
 
2m expression vector was
cotransfected with linearized BaculoGold™ baculovirus DNA
(PharMingen) into High Five™ (BTI-TN-5B1-4) cells (Invitro-
 
gen) using the Lipofectin Reagent
 
®
 
 (GIBCO BRL) by following
the manufacturer’s protocol. Recombinant virus was collected 5 d
after transfection, amplified, and cloned by serial dilution method.
The virus with highest level of mCD1d secretion was used for pro-
tein production. Soluble protein was produced by infecting adher-
ent High Five™ cells at multiplicity of infection of 5–10. mCD1d-
 
containing supernatant was harvested on days 4–5 after the infection,
dialyzed against 0.15 M sodium phosphate buffer, pH 7.4, and
passed over Ni–agarose (QIAGEN) for one-step affinity purifica-
tion. Purified mCD1d protein was biotinylated with BirA enzyme
(Avidity) following the manufacturer’s protocol. 
 
a
 
-GalCer–loaded
mCD1d was tetramerized by adding neutravidin–PE (Molecular
Probes) in 4:1 molar ratio. “Unloaded” mCD1d tetramers were
prepared by preincubating biotinylated protein with an equivalent
amount of 
 
a
 
-GalCer dilution vehicle. For flow cytometry staining,
2.5–5 
 
m
 
g of tetramerized mCD1d was used.
 
T Cell Hybridomas.
 
The derivation and characterization of
the mCD1d-autoreactive NK T cell hybridomas N38-2C12
(hereafter 2C12), N38-2H4 (hereafter 2H4), DN3A4-1.2 (here-
after 1.2), and DN3A4-1.4 (hereafter 1.4) has been described pre-
 
viously (16, 40). A V
 
b
 
8.2 CD4
 
1
 
 T cell hybridoma, 780D5, was
provided by K. Jensen (La Jolla Institute for Allergy and Immu-
nology, La Jolla, CA). mCD1d-restricted V
 
a
 
14
 
2
 
 hybridomas
VIII24 (V
 
a
 
3.2V
 
b
 
9) and VII68 (V
 
a
 
4V
 
b
 
11), a gift of Dr. S.
Cardell (Lund University, Lund, Sweden), have been previously
described (41).
 
Competition for Tetramer Binding.
 
The minimal amount of
mCD1d–
 
a
 
-GalCer–neutravidin–PE tetramer required for stain-
ing of the 1.2 hybridoma was determined by titration of the tet-
ramers. Increasing amounts of competitors were incubated with
1.5 
 
3 
 
10
 
4
 
 1.2 hybridoma cells for 15 min before the addition of
 
1
 
Abbreviations used in this paper:
 
 DN, double-negative; 
 
a
 
-GalCer, 
 
a
 
-galac-
tosylceramide; IELs, intestinal intraepithelial lymphocytes; LAK, lym-
phokine-activated killer. 
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0.75 
 
m
 
g (0.5 
 
m
 
M) of PE-labeled, 
 
a
 
-GalCer–loaded mCD1d tet-
ramers. Competitors included 
 
a
 
-GalCer–loaded mCD1d and
hCD1d monomers and dimers, using proteins derived from
 
Drosophila melanogaster
 
 SC2 cells, as well as 
 
a
 
-GalCer–loaded
mCD1d tetramer, made using unlabeled neutravidin. After addi-
tion of the labeled tetramers, the cells were incubated for 2 h at
4
 
8
 
C, washed extensively, and analyzed by flow cytometry.
 
Mice and In Vivo Treatments.
 
C57Bl/6 mice were purchased
from the The Jackson Laboratory. BALB/c mice and 
 
b
 
2m
 
2
 
/
 
2
 
mice on the C57Bl/6 background were offspring of stock origi-
nally obtained from The Jackson Laboratory. J
 
a
 
281
 
2
 
/
 
2
 
 mice on
the C57Bl/6 background have been previously described (42).
mCD1d1
 
2
 
/
 
2
 
 mice on the C57Bl/6 background were generated
originally by the laboratory of Dr. L. Van Kaer and provided by
Dr. K. Andrews (University of California, Los Angeles, CA). All
mice were maintained under specific pathogen–free conditions at
the vivarium of the La Jolla Institute for Allergy and Immunology
and were used between 6 and 15 wk of age. For experiments
with primed animals, mice were injected intravenously with 4 
 
m
 
g
of 
 
a
 
-GalCer or an equivalent volume of vehicle and killed at the
times indicated (see Figs. 6 and 7) for analysis.
 
Cell Preparation.
 
Single-cell suspensions were prepared from
the liver, spleen, thymus, bone marrow, lymph nodes, and intesti-
nal intraepithelial lymphocytes (IELs). Liver was perfused with
PBS via the portal vein until the liver was opaque and pressed
 
through a 70-
 
m
 
m cell strainer (Becton Dickinson). Total liver
cells were then resuspended in a 40% isotonic Percoll solution
(Amersham Pharmacia Biotech) underlaid with a 60% isotonic
Percoll solution. After centrifugation for 20 min at 900 
 
g
 
, mono-
nuclear cells were isolated at the 40/60% interface. The cells were
washed once with RPMI 1640 medium (Life Technologies) sup-
plemented with 5% FBS (HyClone). For the spleen, lymphocytes
were isolated by separation of total spleen cells on a lympholyte
gradient (Cedarlane Labs.). Bone marrow cells (femur, tibia) were
depleted of B cells using magnetic separation. CD19 microbeads
(Miltenyi Biotec) were incubated with bone marrow cells,
washed, and run over a column as per the manufacturer’s proto-
col. To isolate IELs, the small intestine was opened longitudinally
and flushed of fecal content. The intestine was then cut into 0.5-cm
pieces, transferred into 250-ml Erlenmeyer flasks, and shaken
three times at 200 rpm for 30 min, each time at 37
 
8
 
C, in HBSS
 
without Ca
 
2
 
1
 
 or Mg
 
2
 
1 and containing 1 mM dithiothreitol
(Sigma-Aldrich). The cell suspensions were passed through a 60-mm
nylon mesh, and cells were pelleted by centrifugation at 1,200
rpm. The cell pellets were resuspended in 40% Percoll, layered
over 70% Percoll, and centrifuged at 900 g for 20 min. Cells from
the interface were collected and washed once before analysis.
Flow Cytometry and Intracellular Cytokine Staining. For charac-
terization of the mCD1d–a-GalCer tetramer, cells isolated from
various organs were resuspended in PBS staining buffer contain-
ing 2% BSA and 0.02% NaN3. Cells were incubated for 15 min at
48C with the blocking 2.4G2 anti-FcgR mAb and neutravidin
(Molecular Probes) in a twofold excess of the neutravidin–PE
contained in the amount of tetramer to be used for the staining.
Neutravidin blocking was done to avoid any nonspecific binding
of the neutravidin to biotin on the cells. Staining of FITC-, PE-,
Cy-Chrome–, and allophycocyanin-conjugated mAbs was done
simultaneously with the tetramer in PBS staining buffer at 238C
(room temperature) for 20 min. Cells were washed twice, and
staining with biotinylated mAb was performed at 48C for 20 min.
After washing cells, tricolor-conjugated streptavidin was added as
a secondary staining reagent for the biotinylated mAb and incu-
bated for 15 min at 48C, and cells were washed two times before
analysis. mAbs used in this study include FITC-, Cy-Chrome–,
or allophycocyanin-labeled anti–TCR-b clone H57-597, biotin-
ylated or PE-labeled anti-NK1.1 clone PK136, Cy-Chrome–
labeled anti-CD4 clone RM4-4, allophycocyanin-labeled anti-
CD8a clone 53-6.7, FITC-labeled anti-CD5 clone 53-7.3,
FITC-labeled anti-CD44 clone IM7, biotinylated anti-CD69
clone H1.2F3, FITC-labeled anti-Vb2 clone B20.6, FITC-
labeled anti-Vb7 clone TR310, FITC-labeled anti-Vb8.1/8.2
clone MR5-2, and FITC-labeled anti-Vb12 clone MR11-1
(PharMingen). For intracellular staining, cells were incubated
with blocking 2.4G2 anti-FcgR mAb and neutravidin (Molecu-
lar Probes) and then surface stained with TCR-b–FITC and ei-
ther tetramer or anti-NK1.1–PE at 238C. Cells were permeabi-
lized using Cytofix/Cytoperm Plus™ (PharMingen) and stained
using either FITC-labeled anti–IL-4 clone BVD4-1D11 or
FITC-labeled anti–IFN-g clone XMG1.2 (PharMingen) accord-
ing to the manufacturer’s protocol.
Enrichment of CD1d–a-GalCer Tetramer–positive Cells. Thy-
mocytes were enriched for tetramer-positive cells using anti-PE
microbeads (Miltenyi Biotec). In brief, cells were prepared as de-
scribed above, passed through a 30-mm filter, and incubated at
48C with blocking 2.4G2 anti-FcgR mAb and neutravidin for 15
min. Cells were stained at 238C with the tetramer for 15 min at
room temperature, washed, and incubated with the appropriate
amount of anti-PE microbeads. Magnetic separation was per-
formed according to the manufacturer’s instructions.
Results
mCD1d and hCD1d Multimers Bind Specifically to NK T
Cell Hybridomas. Initially we attempted to make CD1d
tetramers by refolding the heavy chain and b2m from bac-
teria in the presence of a-GalCer. As we did not succeed in
this endeavor, we turned to the native CD1d molecules
produced in insect tissue culture cells. These molecules had
been shown previously to be capable of forming a-Gal-
Cer–CD1d complexes in vitro that are antigenic for NK T
cells (37). a-GalCer–loaded monomers were formed by in-
cubation of soluble recombinant CD1d molecules with the
lipid, while dimers of mCD1d or hCD1d were formed us-
ing the anti-CD1d antibody 2B9 after lipid antigen load-
ing. Both dimers bind specifically to the Va14Vb8 NK T
cell hybridomas 1.2 (Fig. 1 A) and 2C12 (data not shown).
The level of staining by the hCD1d dimers was equivalent
to or greater than that of the mCD1d dimers, consistent
with the cross-reactivity of hCD1d for these two cells (22).
The mCD1d dimer also stained the Va14Vb10 hybridoma
1.4. The signal was reduced, however, despite approxi-
mately equivalent levels of TCR-b staining of this hybrid-
oma. Interestingly, the hCD1d–a-GalCer dimers did not
stain 1.4 at all, in agreement with a previous report of the
poor cross-reactivity for hCD1d by this T cell (22). Vehi-
cle-treated or “unloaded” CD1d dimers did not stain any
of the hybridomas. a-GalCer–loaded mCD1d tetramers
also stained the NK T cell–derived hybridomas (Fig. 1 B).
There was a lower background, a more pronounced shift
for the positive cells, and more evident reactivity of 1.4,
which reacted only weakly with the mCD1d dimers. In
most cases there was little reactivity of unloaded mCD1d
tetramers, although weak staining of 2C12 was observed.744 Tracking a Lipid Antigen Response with Tetramers
This last result is in agreement with the ability of 2C12 to
respond to plates coated with the insect cell–derived
mCD1d, even in the absence of a-GalCer (37). Besides the
Va14Vb8 and Vb10 hybridomas shown in Fig. 1 B, the
tetramers also stained the Va14Vb7 NK T cell hybridoma
2H4 (data not shown), suggesting that NK T cells with the
invariant TCR a chain paired with diverse b chains are
likely to be tetramer positive. We did not detect any bind-
ing of either a-GalCer–loaded or unloaded mCD1d tet-
ramers to two CD1d-restricted but non-Va14–positive T
cell hybridomas, VIII24 and VII68. This is consistent with
the inability of a-GalCer to augment the mCD1d reactiv-
ity of these T cells (16) and with the inability of these hy-
bridomas to recognize plate-bound mCD1d molecules
(Naidenko, O., and M. Kronenberg, data not shown). Ad-
ditionally, 780D5, a Vb8.2 hybridoma that is not CD1d
reactive, failed to bind the mCD1 tetramer, regardless of
the presence of a-GalCer.
Competition for Tetramer Binding by Unlabeled CD1d Multi-
mers. We performed competition experiments to confirm
the specificity of tetramer staining, as well as to get an esti-
mate of the relative affinities of different CD1d–a-GalCer
complexes for a Va14Vb8 TCR (Fig. 2). mCD1d mono-
mers were the least effective competitors, consistent with
the inability of these monomers to stain NK T cells (data
not shown). mCD1d dimers were slightly more effective
than monomers, with the strongest inhibition achieved
with mCD1d tetramers. Therefore, we conclude that ef-
fective competition required mCD1d multimerization, and
the competitors were active in the low micromolar con-
centration range. Interestingly, hCD1d was a more effec-
tive competitor for binding to 1.2 than the homologous
mCD1d molecule. hCD1d monomers were nearly as effec-
tive as mCD1d dimers, whereas hCD1d dimers were as ef-
fective as mCD1d tetramers. This heteroclitic reactivity of
the 1.2 TCR for hCD1d also was evident from IL-2 release
assays carried out using this cell (22). Judging from the re-
sults of functional assays carried out with other NK T cell
hybridomas, this heteroclitic reactivity for hCD1d may not
be unique to 1.2, as 2C12 also responded slightly more
strongly to hCD1d transfectants (22). Because the mCD1d
tetramer gave somewhat better results than the dimer for
both staining and competition, the remaining experiments
were carried out with the tetrameric reagent.
Tetramer-positive T Cells Express Phenotypic Markers of
CD1d-dependent NK T Cells. We also tested the ability of
the mCD1d–a-GalCer tetramers (hereafter called “tetram-
ers”) to specifically identify NK T lymphocytes in complex
mixtures of cells from the thymus and liver. We used mul-
tiparameter flow cytometry analysis to evaluate cells bind-
Figure 1. Specific CD1d multimer staining of T cell hybridomas. (A)
Comparison of mCD1d and hCD1d dimer staining of the 1.2 and 1.4
NK T cell hybridomas. (B) Comparison of mCD1d tetramer staining of
the indicated T cell hybridomas using a-GalCer–loaded and unloaded
tetramers. One representative experiment of three is shown.
Figure 2. Inhibition of tetramer binding by recombinant CD1d mole-
cules. 1.2 hybridoma cells were incubated with the indicated concentra-
tions of competitor molecules before addition of tetramerized mCD1d.
The data are represented as percent of tetramer staining in the absence of
a competitor. As a control, even the highest concentration of competing
multimerized CD1d molecules did not affect the T cell hybridoma stain-
ing with the anti-TCR Cb antibody H57-597 (data not shown). This ex-
periment was repeated three times with similar results.745 Matsuda et al.
ing to the tetramers for coexpression of activation markers,
particular Vb regions, and other cell surface proteins typical
of NK T cells. Based on the parameters we tested, tet-
ramer-positive cells have the same phenotype as CD1d-
restricted NK1.11 T cells, which were defined previously
by a combination of NK1.1 and TCR-b staining. They ap-
pear to be activated, on account of their expression of high
levels of CD44 and CD69 (Fig. 3 A). They also stained
positively for CD5, a marker previously reported to be
found on NK T cells (1). Additionally, the tetramer-posi-
tive cells were compared with conventional T cells from
the same organ for their usage of Vb gene segments. The
invariant Va14 expressed by mCD1d-restricted NK T cells
associates predominantly with, in the order of decreasing
frequency, Vb8.2, Vb7, Vb8.3, Vb2, and Vb8.1 (for re-
view see reference 1). In Fig. 3 B, the bias in the TCR-b
repertoire of tetramer-positive cells is apparent. For exam-
ple, z60% (thymus) or 38% (liver) of the tetramer-positive
cells are either Vb8.2 or Vb8.1 positive, as compared with
8–12% positive in the corresponding conventional T cell
populations from the same organs. The percentage of Vb71
and Vb21 cells in the tetramer-positive T cell population
also reveals this repertoire bias, although more weakly, and
for Vb2 only in the thymus. Staining for an irrelevant Vb
gene segment, Vb12, showed equivalent or decreased ex-
pression by NK T cells. These results corroborate those
from the hybridomas in showing that tetramer staining is
not restricted to a particular Va14–Vb combination.
Tetramer Staining Is Dependent upon CD1d and Ja281 Ex-
pression. To further test tetramer specificity, we analyzed
cells from inbred mouse strains deficient for genes required
for the development of CD1d-dependent NK T cells.
These inbred strains included b2m2/2, CD1d12/2, and
Ja2812/2 mice. The semiinvariant TCR of CD1d-restricted
NK T cells utilizes a Va14Ja281 rearrangement, so the
Ja2812/2 mice also should have decreased tetramer-posi-
tive cells. Additionally, we analyzed BALB/c mice with the
tetramer, to quantitate a-GalCer–reactive, CD1d-depen-
dent NK T cell numbers in a strain that does not express a
form of NK1.1 seen by the antibody PK136. Thymus,
liver, and spleen of each of these mice were analyzed for
tetramer or NK1.1 staining in conjunction with TCR-b
reactivity. Representative tetramer staining of the liver of
each of these strains is shown in Fig. 4 A, and the data for
all three organs are compiled in Fig. 4 B. Only the C57Bl/6
and BALB/c wild-type strains showed significant popula-
tions of tetramer-positive TCR-bint cells, each z25–30%
of the total mononuclear cells in the liver (Fig. 4 B). As ex-
pected,  b2m2/2, CD12/2, and Ja2812/2 mice failed to
stain distinct tetramer-positive populations, staining #1.3%
of the total lymphocytes, which is comparable to the stain-
ing with the unloaded tetramer. The percentage of positive
cells detected with the unloaded tetramer averaged 0.16%
in the thymi, 1.5% in the livers, and 0.37% in the spleens of
C57Bl/6 mice (data not shown).
The gene-deficient mice retain significant populations of
NK1.11 T cells in the liver, however, averaging 6.7% in
CD1d12/2, 3.8% in b2m2/2, and 7.6% in Ja2812/2 mice,
reflecting the presence of populations of Va142 and
CD1d-independent NK T cells. As in the liver, the great
majority of NK1.11 T cells are also tetramer positive in the
thymus. This was less evident in the spleen, where the ef-
fect of either CD1d1 or b2m deficiency on the percentage
of NK1.1 T cells was modest, reflecting the presence of a
population of CD1d-independent NK T cells in that site.
Additionally, whereas the two inbred strains are similar
with regard to the distribution of tetramer-binding cells,
BALB/c mice showed an approximately twofold increase
in tetramer-positive T cells in the thymus compared with
the C57Bl/6 strain (0.7 6 0.2% in C57Bl/6 as compared
Figure 3. Tetramer-positive cells have the expected phenotypic mark-
ers of NK T cells. (A) Phenotypic analysis of tetramer-positive cells in the
thymus. Histogram overlays of tetramer-positive TCR-bint cells (open
histogram) and control stainings (shaded histogram) reveal the tetramer-
positive population to be CD51CD44highCD691. Conventional T cells
served as the control staining for CD44, and for CD5 and CD69, back-
ground staining was used due to the presence of conventional T cells
staining positive for these markers. (B) Tetramer-positive T cells show a
bias in Vb gene segment usage as compared with conventional T cells.
Conventional T cell controls are the lymphocytes expressing high levels
of TCR-b in the thymus (upper left gate in A) and TCR-bhigh and
NK1.12 T cells in the liver. Each of these figures is derived from two ex-
periments with similar results.746 Tracking a Lipid Antigen Response with Tetramers
with 1.4 6 0.1%), although this increase was not reflected
in the spleen or liver (Fig. 4 B).
Tissue Distribution and Phenotype of Tetramer-reactive Cells.
NK T cells are known to be localized in the thymus, liver,
spleen, and bone marrow (1). We sought to test whether
we could detect CD1d-dependent NK T cells in each of
these sites using tetramers and if they are present in any
other locations. Fig. 5 A shows representative data from
this analysis. a-GalCer–reactive NK T cells could be de-
tected in unfractionated cells from the liver, spleen, and
thymus and in B cell–depleted bone marrow. NK T cells
also could be detected in peripheral lymph nodes and in the
lymphocyte gate of IEL preparations. In each case, the re-
active cells had the characteristic TCR-b intermediate
phenotype (Fig. 5 A). We also analyzed CD4 and CD8
coreceptor expression by the tetramer-reactive T cells.
Without a means to directly detect the specific TCR of
NK T cells, investigators have previously used differences
in coreceptor expression, along with an analysis of CD1d-
deficient mice, to differentiate between three populations
of NK T cells (25–27). Two of these populations, CD1d-
independent cells and CD1d-dependent but Va142 cells
with diverse TCRs, are more prevalent in the spleen and
bone marrow, and they include some CD81 T lympho-
cytes. By contrast, the third subpopulation, consisting of
NK T cells that are CD1d dependent, a-GalCer reactive,
and mostly Va141, which is most enriched in the thymus
and liver, has not been reported to contain CD81 cells.
Analysis with tetramers confirmed these earlier findings.
a-GalCer–reactive cells are either CD41 or double-nega-
tive (DN) in every peripheral organ analyzed (Fig. 5 A).
This pattern of coreceptor expression is particularly striking
in IELs from the small intestine, because TCR-a/b1 IELs
are typically .80% CD81. Although there is a small dou-
ble-positive population evident in the thymus (Fig. 5), this
was not consistently reproducible and it is not known if
there are double-positive precursors of the major CD41
and DN, tetramer-positive thymocyte populations.
Because NK T cells may lose NK1.1 expression, we ana-
lyzed T lymphocytes (TCR-b1) for coexpression of NK1.1
and reactivity with the tetramers. The results from this anal-
ysis are compiled in Fig. 5, B and C. The great majority of
tetramer-positive cells in the thymus, liver, and bone mar-
row are also NK1.11 (Fig. 5 B). In lymph node and IELs,
by contrast, only a minority expresses NK1.1. The poten-
tially a-GalCer–reactive populations in the lymph node and
the intestine therefore could have been overlooked, in part
due to diminished NK1.1 expression. When the opposite
analysis was done by gating on NK1.11 T cells and enu-
merating the tetramer-positive cells, we found that the vast
Figure 4. Tetramer binding is
dependent upon CD1d and
Ja281 expression. (A) Represen-
tative analysis for expression of
TCR-b and either tetramer (top
row) or NK1.1 (bottom row) of
liver mononuclear cells from the
indicated strains of mice. The
numbers indicate the percentage
of the liver mononuclear cell
preparation that is positive. (B)
Comparison of the percentages
of tetramer-positive T cells and
NK1.11 T cells in the thymus,
liver, and spleen for the different
strains of mice. The average val-
ues for the indicated number of
mice of each strain are shown.747 Matsuda et al.
majority of thymus and liver NK1.11 T cells were tetramer
positive, in contrast to those in the bone marrow and spleen
(Fig. 5 C). This is reflective of the previously described dif-
ferences in the distribution of the Va141 and other NK T
cell populations (25–27). The lymph node was similar to
the spleen and bone marrow in having a significant popula-
tion of NK1.11, tetramer-negative T lymphocytes. IELs
contain very few NK1.11 T cells, and therefore this analysis
for the percentage of tetramer-positive lymphocytes among
NK1.11 T cells could not be carried out. Some of the
NK1.11 cells that are not also tetramer positive in spleen,
bone marrow, and elsewhere could be CD1d-dependent T
cells with diverse TCRs (41). We cannot currently identify
this CD1d-dependent population with CD1d multimers,
however, regardless of whether the cells express NK1.1, be-
cause the ligands they require are mostly uncharacterized.
Furthermore, as suggested by the analysis of two hybrid-
omas that fit into this category, it is unlikely that the un-
loaded tetramers can detect the majority of these cells. To
determine if the tetramers might bind to cell types other
than T cells, we also analyzed the TCR2 cells in various or-
gans. In the thymus, liver, B cell–depleted bone marrow,
and IELs, essentially all tetramer-positive cells were TCR-b1
(Fig. 5 A). A population of NK1.12TCR2 cells with di-
verse levels of tetramer binding reproducibly could be ob-
served in the spleen and lymph node (Fig. 5 A); these cells
constituted z2% of the TCR-b2 cells in each of these or-
gans. Staining with the unloaded tetramer revealed the same
population, indicating that binding of the tetramer to these
cells does not require a-GalCer. The majority of these
TCR2, tetramer-positive cells are NK1.12 and positive for
the B cell marker CD19 (data not shown). Additionally, in
the liver, spleen, and lymph nodes, a very minor population
(0.26–0.3% of total TCR2 cells) was both tetramer and
NK1.1 positive (data not shown). Although these data are
intriguing, the specificity and significance of the reactivity
of unloaded CD1d tetramers with a small subset of B lym-
phocytes and NK cells remains to be determined.
Figure 5. Frequency and phenotype of tetramer-binding cells from various organs of C57Bl/6 mice. (A) Tetramer staining and the CD4/CD8 pheno-
type of the tetramer-positive cells. Depicted are representative data of cells from the thymus, liver, bone marrow (BM), spleen, peripheral lymph nodes
(LN), and IELs. The percentages indicate the proportion of tetramer-positive T cells in the lymphocyte gate. For each organ, the gated tetramer-positive
cells were analyzed for their CD4 and CD8 phenotype. (B) Analysis of NK1.1 expression by cells from different organs gated for tetramer binding. (C)
Analysis of tetramer reactivity of cells from different organs gated for NK1.1 expression. Percentages and standard deviations were determined based on
the analysis of six mice for the liver, spleen, and thymus and for two mice in the lymph node, bone marrow, and IELs.748 Tracking a Lipid Antigen Response with Tetramers
Potent and Short-lived Cytokine Production by NK T Cells in
Response to a-GalCer. The tetramer provides the oppor-
tunity to follow an NK T cell population in response to an-
tigen administration. We injected a-GalCer and analyzed
the mice at 2 and 5 h for the production of cytokines by
tetramer-positive cells. At 0 h, very few of the tetramer-
positive cells stain positive for intracellular IFN-g or IL-4
(0.8 6 0.3% IFN-g and 2.4 6 1.0% IL-4 for the liver). We
then analyzed the liver and spleen at 2 h after antigen ad-
ministration. An average of 22% of the cells in the liver at
this time point are tetramer-positive IFN-g1, and 22% are
tetramer-positive IL-41 (Fig. 6 A). For technical reasons,
we were unable to stain for IFN-g and IL-4 concurrently.
It is likely, however, that the majority of NK T cells are se-
creting both cytokines, because an average of 91 6 3% of
the tetramer-positive cells in the liver were producing IL-4
and 85 6 9% of them were making IFN-g. NK T cells in
the spleen also responded rapidly to a-GalCer, although
the average percentage of responding tetramer-positive
cells was lower, 55 6 5% for IL-4 and 48 6 4% for IFN-g.
Strikingly, this large a-GalCer–responding population in
the liver and spleen almost completely disappeared by 5 h.
Tetramer-positive IFN-g1 cells comprised only 3.7% of
the total lymphocyte population in the liver, and tetramer-
positive IL-41 cells made up 3.4%. The disappearance of
cytokine producing tetramer-positive liver cells parallels a
similar reduction both in the total tetramer-positive cells
(Fig. 6 A) and in the CD41 tetramer-positive cells in par-
ticular (Fig. 6 B). At 0 and 2 h after antigen, CD41 cells
comprise z70% of the tetramer-positive population. By
5 h, however, this CD41 population is reduced to 16.6%.
This suggests that there may be a selective early loss of the
CD41 cells or of CD4 expression. There is a reduction in
the number of tetramer-positive cells 5 h after antigen in the
spleen, although this reduction is less extreme than in the
liver (data not shown). Although the total number of bind-
ing cells and cytokine-producing tetramer-positive cells
decreases rapidly after antigen, there is a concomitant in-
crease in the number of IFN-g–producing, tetramer-nega-
tive cells in the liver. This tetramer-negative and cytokine-
producing population was found to be predominantly
NK1.11, and these cells do not contain IL-4. They com-
Figure 6. Kinetics and tissue
specificity of in vivo response of
NK T cells to a-GalCer. (A)
Time course of the response in
the liver to intravenous injection
of a-GalCer. Intracellular cyto-
kine staining was carried out as
described in Materials and Meth-
ods. (B) CD41, tetramer-posi-
tive cells in the liver are rapidly
and selectively diminished after
a-GalCer injection. The per-
centage of CD41 cells among
the gated tetramer-positive cells
at various time points is shown.
(C) Enrichment of tetramer-pos-
itive cells in the thymus using
magnetic beads. (D) Thymocytes
fail to produce IL-4 or IFN-g
2 h after a-GalCer injection.
Three mice were analyzed
showing similar results for each
time point depicted. Percent-
ages for individual mice are
shown in the figure, with aver-
ages of several mice in the text.749 Matsuda et al.
prised an average of z2% of the liver mononuclear cells at
2 h and 11% by 5 h. A similar pattern was identified in the
spleen (data not shown). These cells express higher levels of
NK1.1 (mean fluorescence 5 504) than tetramer-positive
NK T cells (mean fluorescence 5 84), and therefore it is
likely that they are NK cells that have been rapidly acti-
vated in response to NK T cells. This would be consistent
with a recent report (43).
The data presented above suggest that the tetramer-
binding cells in the liver are fully responsive to a-GalCer,
whereas those in the spleen are only partially responsive.
We therefore also analyzed the NK T cells in the thymus.
The thymus has a 40–50-fold reduced percentage of tet-
ramer-positive cells compared with mononuclear cells from
the liver. We enriched for the tetramer-binding thymocyte
population by staining the cells ex vivo with tetramer fol-
lowed by enrichment of the NK T cell using magnetic
beads. In this way, the percentage of tetramer-positive thy-
mocytes was increased from ,1% to .60% (Fig. 6 C). Al-
though the enriched thymocytes contained z60% tet-
ramer-positive cells, none of these cells from mice
immunized 2 h earlier (Fig. 6 D) or 5 h earlier (data not
shown) with a-GalCer contained intracellular IL-4 or
IFN-g. Consistent with our intracellular staining results,
there was no reduction in the number of tetramer-positive
thymocytes after a-GalCer injection (Fig. 7).
Long-Term Depletion of Tetramer-positive NK T Cells in the
Liver in Response to a-GalCer. To assess the reappearance
or recovery of the a-GalCer–reactive T cells, C57Bl/6
mice were injected intravenously with 4 mg of a-GalCer
and analyzed 1 wk later for the presence of NK T cells.
Representative flow cytometry data are shown in Fig. 7 A.
The livers of a-GalCer–primed mice have reduced num-
bers of tetramer-positive T cells, similar to the numbers ob-
served 5 h after immunization. The majority of the remain-
ing NK1.11 T cells in the liver are tetramer negative, and
both the CD41 and DN tetramer-positive cells were de-
creased (Fig. 7 B). As in the previous cases, the spleen
showed less dramatic but similar changes. In a slightly dif-
ferent protocol, cells from mice primed with 11 mg of
a-GalCer at days 0 and 7 were analyzed 6 wk after the sec-
ond priming. In this case, the percentage of tetramer-posi-
tive cells in the liver remained greatly reduced, averaging
2.5% of total monocytes. Collectively, these data indicate
that the decrease in tetramer-positive cells is not due to a
transient downregulation of the NK T cell TCR. In the
thymus, by contrast, tetramer-positive thymocyte numbers
are unchanged at 1 wk after lipid antigen priming (Fig. 7
A) and at 6 wk (data not shown), and the proportions of
CD41 and DN tetramer-positive thymocytes are unaltered
(Fig. 7 B).
Discussion
CD1d-dependent NK T lymphocytes are a distinct T
cell subset that may be important for the regulation of the
immune response (3–5, 7, 9, 42). Reliable cell surface
markers that define this population have been lacking,
however, and therefore it has been difficult to precisely
enumerate these lymphocytes in ontogeny or during im-
mune responses. The combination of NK1.1 and TCR-b
expression frequently has been used to define CD1d-
dependent NK T cells. This has several important limita-
tions, including the inability of the available mAbs to detect
the NK1.1 allele in most mouse strains, the expression of
NK1.1 by T cells that are not CD1d reactive (44, 45), and
the possible loss of NK1.1 expression by activated NK T
cells (24). In this report, we describe the generation and use
of several kinds of CD1 multimers. These reagents, particu-
larly a-GalCer–loaded mCD1d tetramers, have allowed us
to identify CD1d-reactive NK T cells based solely upon
their TCR specificity.
mCD1d dimers and tetramers were both found to be ca-
pable of staining a-GalCer–reactive T lymphocytes, al-
though tetramers gave a more reproducible and uniform
staining. The reactivity requires multimerization, and con-
sistent with this, mCD1d monomers were relatively inef-
fective competitors for tetramer binding. a-GalCer load-
ing, which was carried out at neutral pH, is also required in
most cases for tetramer binding. These data imply that
a-GalCer can effectively replace the endogenous lipid
present in CD1d molecules derived from insect cells and
that the a-GalCer–CD1d complexes thereby formed are
Figure 7. C57Bl/6 mice primed with a-GalCer fail to recover tet-
ramer-positive T cell numbers in the liver 1 wk after priming. (A) Repre-
sentative flow cytometry analysis of tetramer-positive T cells and NK1.11
T cells in thymi and livers of vehicle- or a-GalCer–primed mice. (B)
CD4/CD8 phenotype analysis of tetramer-positive T cells found in the
livers and thymi of vehicle- or a-GalCer–primed mice. Three mice were
analyzed, each for the vehicle and a-GalCer.750 Tracking a Lipid Antigen Response with Tetramers
highly stable. The effective binding at neutral pH agrees
with our previous findings on the pH dependence of the
lipid–CD1d interaction, which were obtained using surface
plasmon resonance to measure the binding of soluble re-
combinant CD1d to immobilized lipid (37). In that previ-
ous study, however, the koff was rapid and the measured
half-life of the a-GalCer–CD1d complexes was z7 min
(37). It is likely that several factors contribute to the appar-
ently increased stability of a-GalCer binding in the ex-
perimental system used in this report. First, rebinding of
a-GalCer should be greatly facilitated in the presence of
multimerized CD1d molecules, as opposed to mCD1d
monomers flowing over a biosensor chip that contains a
low density of ligand. Second, as we noted previously (37),
because of the chemistry of the a-GalCer immobilization,
it is likely that only one of the two hydrophobic chains of
the glycosphingolipid was available for CD1d binding in
the surface plasmon resonance study, whereas both chains
were available in the experiments reported here. The re-
sults from a number of control experiments demonstrated
the specificity of the CD1d multimers. First, the flow cy-
tometry analysis of T cell hybridomas with the multimers
was highly consistent with the functional assays of these
cells. Concordant IL-2 release and binding results were ob-
tained for reactivity to mCD1d in the absence of a-GalCer,
for the a-GalCer requirement for different CD1d restricted
T cells, and for the analysis of cross-reactivity with hCD1d
(16, 21, 22). Second, the distribution and phenotype of tet-
ramer-binding cells agrees with previous phenotypic analyses
of CD1d-dependent NK T lymphocytes. The reactive cells
express activation markers, lack CD8, have preferential ex-
pression of Vb8 and Vb7, and are predominantly NK1.11.
Additionally, as suggested by previous studies (25–27), the
percentage of CD1d-dependent NK T cells in the NK1.1
subset was greater in thymus and liver compared with spleen
and bone marrow. Third, tetramer-binding cells were
greatly decreased in strains deficient for expression of the
CD1d antigen-presenting molecule or the Ja281 component
of the invariant TCR a chain, consistent with the inability
of these strains to respond to a-GalCer (16, 18).
Staining with the tetramers yielded several unexpected
results regarding the phenotype and distribution of the re-
active cells. First, although the majority of CD1d-depen-
dent NK T cells are in the thymus, liver, spleen, and bone
marrow, populations also were revealed in lymph nodes
and IELs. Based on these findings, we conclude that
CD1d-dependent and a-GalCer–specific NK T cells are
likely to be found in most places where conventional T
cells also are located, although the percentage of T cells that
fit into this category clearly varies between organs. Second,
the great majority of freshly isolated NK cells did not stain
with the tetramers, nor did lymphokine-activated killer
(LAK) cells generated by culture with IL-2 (Naidenko,
O.V., L. Brossay, and M. Kronenberg, unpublished obser-
vations). Previously, we had shown that expression of
mCD1d by RMA-S cells inhibited LAK activity, although
this was only revealed upon repeated culture with IL-2.
This result suggested an interaction of CD1 with an inhibi-
tory NK receptor (46). The negative results obtained with
the tetramers on LAK cells are not consistent with this hy-
pothesis, but the tetramers might not be able to bind to a
putative inhibitory receptor if the RMA-S cells provide a
ligand required for this interaction. The altered glycosyla-
tion pattern of the insect cell–derived CD1d molecules also
might prevent binding. Finally, the affinity might be too
low to detect binding, by analogy with the interaction of
CD8 with most MHC class I tetramers. It is clear, how-
ever, that some NK receptor–class I interactions have a
higher affinity (32–34, 47, 48). Further experiments will be
required to uncover the basis for this CD1d-mediated inhi-
bition of NK cells.
NK T cell populations exhibit a dynamic response to
lipid antigen stimulation. 2 h after antigen injection, nearly
all of the tetramer-positive cells in the liver and spleen are
making both IFN-g and IL-4; there are almost no cells po-
larized to either a Th1 or Th2 cytokine pattern. Rather
than expanding in response to antigenic stimulation, how-
ever, by 5 h, .80% of the responding NK T cells can no
longer be visualized as TCR1, CD41, or IL-4–containing
cells. What is the fate of the NK T cells that have disap-
peared from the liver and spleen? We did not find a major
increase in the number of tetramer-positive cells in any or-
gan that was analyzed, and therefore we consider it unlikely
that the NK T lymphocytes have migrated out to another
site after activation. TCR downregulation after antigen ac-
tivation is a possibility, but this would have to occur con-
comitantly with a loss of CD4 expression and intracellular
IL-4. Furthermore, the population of tetramer-positive
cells is greatly reduced even 6 wk after antigen stimulation.
Based on these results, we hypothesize that the majority of
NK T cells in liver and spleen undergo activation-induced
cell death in response to lipid antigen stimulation and that
the renewal of this population is surprisingly slow. Consis-
tent with this, Eberl and MacDonald have also provided
evidence for a decrease in NK T cell numbers after a-Gal-
Cer priming (43). They also have demonstrated that NK T
cells rapidly undergo activation-induced cell death after
stimulation with either anti-CD3 or IL-12 injection (49).
Although they report a greater degree of recovery of the
NK T cells based upon NK1.1 and TCR staining at various
time points after anti-CD3 injections, their observations
with a-GalCer parallel ours. However, we find that the
number of tetramer-binding cells does not increase propor-
tionately with the increase in NK1.11 T cells, even 1 wk
after antigen administration.
A population of tetramer-negative, NK1.11 cells, which
contains intracellular IFN-g but not IL-4, appears after 5 h.
These could be NK cells that have been activated rapidly
by NK T cell cytokines, suggesting a close connection be-
tween these two lymphocyte populations. This interpre-
tation is consistent with the higher level of NK1.1 expres-
sion by these cells, as well as with earlier work showing an
a-GalCer–mediated increase in NK cell activity (43, 50–52)
and a previous study demonstrating the production of IFN-g
by NK cells after NK T cell activation (53). It therefore is
possible that much of the IFN-g that we (19) and others751 Matsuda et al.
(20, 54) have reported in the blood of mice injected with
a-GalCer 16 h previously is derived from NK cells that
have been activated by NK T cells.
Although CD1d-dependent NK T cells in the liver and
spleen respond rapidly and then disappear and apparently
die, tetramer-binding cells in the thymus undergo neither
response. One possible explanation for these results is that
a-GalCer is incapable of reaching the thymus tissue. Consis-
tent with this, thymic NK T cells can respond to a-GalCer
when stimulated in suspension culture with the lipid in the
absence of exogenous APCs. Alternatively, we speculate that
thymocytes may be prevented from responding in vivo by
inhibitory receptors or by some other means. Interestingly, it
has been shown recently, based upon long-term BrdU label-
ing, that thymus NK T cells are turning over more slowly
than those in the liver (55), consistent with these cells being
in a quiescent or negatively regulated state. Further experi-
ments will be required to establish the mechanism for the
striking difference in NK T cell responses to lipid antigen in
the thymus as compared with the periphery.
The data presented here provide direct insight into the
surprising dynamics of antigen-activated NK T cells in
vivo. It should be noted that a-GalCer exposure does not
lead to the all-encompassing death of NK T cells in the
spleen and liver. In fact, the NK T cell responses of a-Gal-
Cer–primed mice to a second antigen exposure have been
reported to be highly polarized in a Th2 direction (19, 20),
or in some cases a Th1 direction (56, 57). The properties
that permit the survival and polarized cytokine response of
a minority of NK T cells in certain sites remain to be deter-
mined. Once natural antigens for NK T cells are identified,
it also will be of great interest to determine if they have in
vivo effects similar to those of a-GalCer. It is likely that the
use of tetramers, which has permitted the definition of
these new problems in NK T cell biology, will also con-
tribute to their eventual solution.
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